The U.S. Patent & Trademark Office’s Patent Trial & Appeals Board found that 16 of Norred’s claims were unpatentable, upholding Medtronic’s challenge to the patent, PTO records show.
The patent board ruled that the patent was invalid as anticipated based on prior art cited in the patent application.
Norred, who plans to appeal the decisions, according to legal filings, claims that CoreValve used his patent in developing the aortic valve replacement and that Medtronic continued to infringe the patent after acquiring CoreValve for $700 million in 2009.
The physician’s 2013 patent infringement lawsuit, filed in the U.S. District Court for Kansas, was stayed until a trio of inter partes reviews by the PTAB were concluded, according to court documents.
In May 2014, Medtronic and TAVI arch-rival Edwards Lifesciences (NYSE:EW) buried the hatchet in their long-running patent war with a $750 million settlement that will see Medtronic pay royalties through April 2022 of at least $40 million annually.